Compare IDEXX Laboratories, Inc. (IDXX) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Oscar Health Inc — how do they compare? IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B), while Oscar Health Inc trades at $29.58 (market cap $8.63B). The key difference: IDEXX Laboratories, Inc. is far larger — about 5.4× Oscar Health Inc's market cap, and Oscar Health Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | OSCR | |
|---|---|---|
Market Cap | $46.22B | $8.63B |
Sector | Health | Health |
52-Week High | $766.68 | $32.18 |
52-Week Low | $526.44 | $10.85 |
Enterprise Value | $47.12B | $4.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Oscar Health (OSCR) trades at $29.61, up 7.01% today, with technical indicators showing a bearish trend but oversold RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with $1.1 per share, and raised its full-year outlook amid membership growth and cost control. Revenue surged 70% year-over-year to $4.9 billion for the first half of 2026, driving a net income turnaround to $551 million for the full year 2026.
The outlook is positive with robust revenue growth and profitability improvements, though risks include competitive pressures and reliance on Obamacare policies. Analysts have a consensus price target of $32.50, suggesting moderate upside, but hold ratings dominate due to execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
